Read about cancer treatment options listed by gene mutation, type of cancer and type of treatment.
I am here because:

I need to know more about genetic testing

I tested positive for an inherited mutation

I am at high risk for breast or ovarian cancer

I have Lynch syndrome

I have been diagnosed with breast cancer

I need to know more about colorectal cancer

I have Jewish ancestry

I need to know more about biomarker testing

I need to know more about endometrial cancer

I have been diagnosed with ovarian cancer

I need to know more about pancreatic cancer

I need to know more about prostate cancer

I need to know more about menopause

I am a healthcare provider

Risk Management & Treatment

Cancer Treatment > Biomarker Testing > Common Biomarker Tests

1
Overview
2
Common Biomarker Tests
3
DNA Damage Repair

Biomarkers used for treatment selection

The following tumor biomarkers may be used to select treatment for the cancer types listed below. Speak with your doctor about other biomarker tests and treatments, which may be available. 

Biomarker Cancer Treatment/s
  Breast Colorectal Endometrial Melanoma Ovarian Pancreatic Prostate

 
BRAFV600E   X   X      

Braftovi (encorafenib)
Braftovi in combination with Mektovi (binimetinib)
Cotellic (cobimetinib)
Zelboraf (vemurafenib) 
BRCA1, BRCA2          X   X Lynparza (olaparib) 
Rubraca (rucaparib)
Zejula® (niraparib)
Epidermal growth factor
receptor (EGFR) mutation testing		   X          

Erbitux (cetuximab)
Vectibix (panitumumab) 
Estrogen/Progesterone receptor
(ER/PR) expression		 X   X        

Aromatase inhibitors (AIs)
Tamoxifen
Raloxifene
Her2neu overexpression X             Herceptin (trastuzumab)
Perjeta (pertuzumab)
Tuksya (tucatinib)
Kadcyla (ado-trastuzumab emtansine) 
Homologous Recombination
Deficiency (HRD)		         X    

Lynparza (olaparib) 
Zejula® (niraparib)
Homologous Recombination Response (HRR) pathway mutations (ATM, BRCA1, BRCA2, BARD1, BRIP1, CDK12, CHEK2, FANCL, PALB2, RAD51B, RAD51C,  RAD51D, RAD54)             X Lynparza (olaparib) 
KRAS mutation   X          

Erbitux (cetuximab)
Vectibix (panitumumab) 
MSI-H (Microsatellite Instability) or MMR-D (Mismatch Repair) X X X X X X X Keytruda (pembrolizumab)
MSI-H (Microsatellite Instability) or MMR-D (Mismatch Repair)   X           Opdivo (nivolumab) 
Yervoy (ipilimumab)
NTRK fusion X X X X X X X Vitrakvi (larotrectinib)
PDL1 expression X             Tecentriq (atezolizumab)
PIK3CA X             Piqray (alpelisib),
Tumor Mutational Burden (TMB) X X X X X X X Keytruda (pembrolizumab)
Last updated July 05, 2020